Coinbase Q2 Earnings and Revenues Miss Estimates, Volumes Rise Y/Y
COIN witnessed lower crypto volatility and lower transaction revenue in the quarter while operating expenses increased.
Operational Update
Total trading volume increased 4.9% year over year to 237 million in the reported quarter. The Zacks Consensus Estimate was pegged at 235 million.
Total revenues of $1.5 billion missed the Zacks Consensus Estimate by 0.5%. The top line, however, increased 3.2% year over year on higher transaction revenues, subscription and services revenues and other revenues.
Total transaction revenues decreased 2.1% year over year to $764.3 million in the quarter. The decline was due to lower consumer transaction revenues as well as institutional transaction revenues. The Zacks Consensus Estimate was pegged at $795 million.
Total subscription and services revenues increased 9.5% year over year to $655.8 million in the reported quarter. The growth was driven by higher stablecoin revenues. The Zacks Consensus Estimate was pegged at $692 million.
Total operating expenses increased 37.5% to $1.5 billion in the quarter due to higher transaction expense, technology and development, sales and marketing and general and administrative expenses as well as other operating expense.
Adjusted EBITDA was $512 million in the reported quarter, which fell 3.2% from the year-ago quarter.
Financial Update
Coinbase exited the second quarter with cash and cash equivalents of $7.5 billion as of June 30, 2025, down 11.8% from 2024-end.
As of June 30, 2025, long-term debt increased 62.6% from 2024-end to $2.9 billion.
Shareholders' equity was $12.1 billion at second-quarter 2025-end, up 17.7% from 2024-end.
Net cash provided by operating activities was $145.7 million in first-half 2025, a drop of 83.7% year over year.
Q3 2025 Outlook
Coinbase expects subscription and services revenues to be in the range of $665-$745 million, driven primarily by higher average crypto prices and stablecoin revenues.
Transaction expenses are expected to be in the mid-teens as a percent of net revenues.
Coinbase expects technology and development and general and administrative expenses to be in the range of $800-$850 million, driven by headcount growth to support international expansion, new product initiatives and strengthening of customer support & security functions.
Coinbase expects sales and marketing expenses to increase quarter over quarter to $190-$290 million, driven by potential variability in performance marketing and customer USDC balances in Coinbase products, which drive USDC reward.
Zacks Rank
COIN currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Peer Releases
American Express Company AXP reported second-quarter 2025 earnings per share (EPS) of $4.08, which beat the Zacks Consensus Estimate by 5.7%. The bottom line climbed 17% year over year. Total revenues net of interest expense amounted to $17.9 billion, which outpaced the Zacks Consensus Estimate by 1%. The top line improved 9% year over year in the quarter under review.
Network volumes of $472 billion rose 7% year over year in the second quarter, driven by higher U.S. consumer spending. Total interest income of $6.3 billion increased 8% year over year and beat the consensus mark by 0.4%.
American Express still anticipates revenues to increase between 8% and 10% in 2025 from the 2024 level of $65.9 billion. Management expects EPS in the range of $15-$15.50, the midpoint of which indicates an improvement of 8.9% from the 2024 level of $14.01.
Bread Financial Holdings ' BFH operating income of $3.14 per share for the second quarter of 2025 beat the Zacks Consensus Estimate by 69.7%. The bottom line improved 18% year over year. Revenues decreased 1.1% year over year to $929 million. The top line also missed the consensus estimate by 0.9%.
Credit sales of $6.8 billion increased 4%, driven by new partner growth and increased general-purpose spending. Our estimate was $6.6 billion. Average loans of $17.7 billion decreased 1%.
Management estimates average receivables to be flat to slightly down from 2024. It expects average credit card and other loans to be flat to slightly down from the 2024 level. Total revenues are estimated to be flat year over year. The net loss rate is guided in the range of 7.8-7.9%.
Virtu Financial 's VIRT second-quarter operating income of $1.53 per share for the second quarter of 2025 beat the Zacks Consensus Estimate by 0.8%. The bottom line improved 84.3% year over year. Revenues increased 47.5% year over year to $929 million. The top line also beat the consensus estimate by 9.4%.
Adjusted EBITDA increased 69.8% to $369.4 million. Adjusted EBITDA margin of 65.1% expanded 860 bps year over year.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
American Express Company (AXP): Free Stock Analysis Report
Virtu Financial, Inc. (VIRT): Free Stock Analysis Report
Coinbase Global, Inc. (COIN): Free Stock Analysis Report
Bread Financial Holdings, Inc. (BFH): Free Stock Analysis Report
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
29 minutes ago
- Globe and Mail
SIS, LLC Announces Successful Go-Live of CRB on Microsoft Dynamics 365 and SIS Construct 365 Project Cost Management
DULUTH, Ga., Aug. 6, 2025 /CNW/ -- SIS, LLC, a Microsoft Solutions Partner for Business Applications and leading implementer of ERP and CRM solutions for the construction industry, is thrilled to announce the successful go-live of CRB Group on Microsoft Dynamics 365 (D365) and SIS Construct 365 Project Cost Management (PCM) solution. This milestone marks a significant step in CRB's digital transformation journey, empowering their teams with cutting-edge tools to drive efficiency, profitability, and growth.
CBC
30 minutes ago
- CBC
Air Canada flight attendants vote to strike if agreement not reached, union says
More than 10,000 flight attendants could strike later this month. Members voted 99% percent in favour to strike if a deal is not reached. A 72 hour strike notice could be issued as soon as Aug. 16 according to the union representing flight attendants.
Globe and Mail
an hour ago
- Globe and Mail
DaVita Stock Down Despite Q2 Earnings Beat, Gross Margin Expands
DaVita Inc. DVA delivered adjusted earnings per share (EPS) of $2.95 in the second quarter of 2025, up 13.9% year over year. The figure surpassed the Zacks Consensus Estimate by 9.3%. GAAP EPS for the quarter was $2.58, reflecting an uptick of 3.2% year over year. DaVita's Revenues in Detail Revenues of $3.38 billion in the second quarter increased 6.1% year over year. The figure topped the Zacks Consensus Estimate by 1.3%. Revenue per treatment in the second quarter of 2025 was $404.6 million, up 3.7% year over year and 1.1% sequentially. Per management, this was primarily driven by normal seasonal improvements, including patients meeting their co-insurance and deductibles. This was partially offset by decreased volume of phosphate binders. Shares of this company plunged nearly 10.1% till last trading. DVA's Segment Details DaVita generates revenues via two sources — Dialysis patient service revenues and Other revenues. The dialysis patient service revenues were $3.21 billion, up 4.8% year over year. Other revenues were $172.7 million, up 37.4% from the year-ago quarter's figure. Per management, the total U.S. dialysis treatments for the second quarter were 7,186,217 or 92,131 per day, on average. This represents a per-day increase of 0.4% on a sequential basis. Normalized non-acquired treatment declined 0.8% year over year in the second quarter of 2025. As of June 30, 2025, DaVita provided dialysis services to around 283,100 patients at 3,175 outpatient dialysis centers, of which 2,662 were U.S. centers while 513 were located across 13 other countries. During the second quarter of 2025, the company acquired one, opened three and closed two dialysis centers in the United States. It also opened six and closed five dialysis centers outside the United States in the same period. As of June 30, 2025, DaVita had approximately 64,400 patients in risk-based integrated care arrangements in its Integrated Kidney Care business, representing $5.3 billion in annualized medical spend. The company also had an additional 9,300 patients in other integrated care arrangements. DaVita's Margin Details In the quarter under review, DaVita's gross profit increased 7% year over year to $1.12 billion. The gross margin expanded 31 basis points (bps) to 33.1%. General & administrative expenses climbed 12.2% year over year to $412.8 million. Adjusted operating profit totaled $705.2 million, reflecting a 4.2% increase from the prior-year quarter's level. Adjusted operating margin in the second quarter contracted 36 bps to 20.9%. DVA's Financial Position DaVita exited second-quarter 2025 with cash and cash equivalents and short-term investments of $739.4 million compared with $511.9 million at the first-quarter end. Total debt (including the current portion) at the end of second-quarter 2025 was $10.26 billion compared with $9.74 billion at the first-quarter end. Cumulative net cash provided by operating activities at the end of second-quarter 2025 was $504.2 million compared with $664 million a year ago. During the three months ended June 30, 2025, DVA repurchased 3.1 million shares for $446 million. DaVita's Guidance DaVita has reiterated its adjusted EPS outlook for 2025. Adjusted EPS for the full year is continued to be projected in the range of $10.20-$11.30. The Zacks Consensus Estimate currently stands at $10.76. Our Take on DVA DaVita ended the second quarter of 2025 with better-than-expected results. The uptick in the company's top and bottom lines and revenue per treatment was encouraging. The per-day increase in total U.S. dialysis treatments for the second quarter on a sequential basis and solid revenues from both sources were encouraging. The opening and acquiring of dialysis centers within the United States and acquiring centers overseas were promising. The gross margin expansion bodes well for the stock. However, the year-over-year decline in normalized non-acquired treatment was disappointing. The contraction of the adjusted operating margin does not bode well for the stock. DaVita's Zacks Rank and Key Picks DVA currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space that have announced quarterly results are GE HealthCare Technologies Inc. GEHC, West Pharmaceutical Services, Inc. WST and Boston Scientific Corporation BSX. GE HealthCare, sporting a Zacks Rank #1 (Strong Buy), reported second-quarter 2025 adjusted EPS of $1.06, beating the Zacks Consensus Estimate by 16.5%. Revenues of $5.01 billion outpaced the consensus mark by 0.7%. You can see the complete list of today's Zacks #1 Rank stocks here. GE HealthCare has a long-term estimated growth rate of 5.8%. GEHC's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 12.5%. West Pharmaceutical reported second-quarter 2025 adjusted EPS of $1.84, beating the Zacks Consensus Estimate by 21.9%. Revenues of $766.5 million surpassed the Zacks Consensus Estimate by 5.4%. It currently flaunts a Zacks Rank #1. West Pharmaceutical has a long-term estimated growth rate of 8.4%. WST's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%. Boston Scientific reported second-quarter 2025 adjusted EPS of 75 cents, beating the Zacks Consensus Estimate by 4.2%. Revenues of $5.06 billion surpassed the Zacks Consensus Estimate by 3.5%. It currently carries a Zacks Rank #2 (Buy). Boston Scientific has a long-term estimated growth rate of 14%. BSX's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.1%. Zacks' Research Chief Picks Stock Most Likely to "At Least Double" Our experts have revealed their Top 5 recommendations with money-doubling potential – and Director of Research Sheraz Mian believes one is superior to the others. Of course, all our picks aren't winners but this one could far surpass earlier recommendations like Hims & Hers Health, which shot up +209%. See Our Top Stock to Double (Plus 4 Runners Up) >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX): Free Stock Analysis Report DaVita Inc. (DVA): Free Stock Analysis Report West Pharmaceutical Services, Inc. (WST): Free Stock Analysis Report GE HealthCare Technologies Inc. (GEHC): Free Stock Analysis Report
